Drugs / NCI-4650
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03480152 | May 2018 → Jun 2019 | colorectal cancer, hepatocellular carcinoma, melanoma | National Cancer Institute (NCI) | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NCI-4650 | “National Cancer Institute (NCI)-4650, a messenger ribonucleic acid (mRNA)-based, Personalized Cancer Vaccine” NCT03480152 ↗ |